Form 4: Adverum Biotechnologies: Leonard Braden Michael Reports Significant Share Purchases

Director Leonard Braden Michael reports purchasing additional shares of Adverum Biotechnologies through BML Investment Partners, L.P.

Summary

• On July 17, 2024, Leonard Braden Michael, a director of Adverum Biotechnologies, indirectly acquired 135,546 shares of common stock at a weighted average price of $7.7459 per share.
• On July 18, 2024, Mr. Michael indirectly acquired another 80,718 shares of common stock at a weighted average price of $9.1149 per share.
• These purchases were made through BML Investment Partners, L.P., where BML Capital Management, LLC serves as the general partner and Mr. Leonard is the managing member.
• Following these transactions, Mr. Michael indirectly beneficially owns 2,182,264 shares through his holdings in BML Investment Partners, L.P.
• Mr. Leonard disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Insider buying can be seen as a positive sign, but the filing itself is simply a disclosure of transactions.

Positives

• The director's purchase of shares could be interpreted as a positive signal about the company's prospects.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common in the biotechnology industry. Investors often monitor such filings for signals about management's confidence in the company's future prospects.

Stakeholder Impact

• Shareholders may view the director's purchase as a positive sign.
• The increased ownership stake could align management's interests more closely with those of shareholders.

Key Dates